Initiative aims to reduce cancer mortality rates by 50% in the next 25 years.
GC Cell announced in a company press release that it will be joining CancerX, part of the US Cancer Moonshot project. Started by the Biden administration, the Cancer Moonshot aims to reduce cancer patient mortality rates by over 50% over the next 25 years. According to the company, it aims to highlight the importance and potential of cell therapy in cancer treatment through participating in the initiative.
"I am pleased to contribute to projects that can change the lives of many patients and their families,” said James Park, CEO, GC Cell.” “The Cancer Moonshot & CancerX provides an expanded opportunity to build diverse collaborative research and partnership frameworks with global companies."
Reference: GC Cell Joins US Cancer Moonshot Project. PR Newswire. October 24, 2023. Accessed October 25, 2023. https://www.prnewswire.com/news-releases/gc-cell-joins-us-cancer-moonshot-project-301966721.html
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.